Phase 2 × Polycythemia Vera × Lymphoid × Clear all
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
NCT05031897 2025-10-30

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

Phase 2 Recruiting
63 enrolled
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT01384513 2022-11-17

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled
NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
NCT00005797 2020-12-10

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
125 enrolled
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00683046 2016-11-22

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

University of Chicago

Phase 2 Completed
204 enrolled 7 charts
NCT00134004 2015-10-06

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
210 enrolled 10 charts
NCT00005641 2012-12-11

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
NCT00005622 2012-10-25

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
72 enrolled
NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
NCT00110045 2012-09-24

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
171 enrolled
NCT00132015 2012-03-15

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled
NCT00006379 2011-12-08

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Case Comprehensive Cancer Center

Phase 2 Completed
58 enrolled
NCT00002504 2011-05-12

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Hoag Memorial Hospital Presbyterian

Phase 2 Completed
NCT00005804 2010-04-02

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed